Abdul Saleem Mohammad
Determination of nitazoxanide in biological matrices by LC-MS/MS technique: method development and validation - Vol.56(2), Apr-June - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 539-545p.
Background: Determination of pharmaceuticals in the biological matrices is essential for
toxicologic and pharmacokinetic applications. The main objective of the current work
was to develop a bioanalytical method for quantifying nitazoxanide in biological samples
by LC-MS/MS. Materials and Methods: Chromatographic elution of nitazoxanide and
linagliptin were achieved on C18
-hypersil (5 μ, 50x4.6mm) stationary phase with mobile
phase consisting of acetonitrile and 0.1% HCOOH (75:15, v/v) processed at 0.8 ml/min
flow rate. Linagliptin was utilized as an internal standard (IS). Results: The method
was linear in the concentration levels of 0.53–21.2 ng/ml with more than 0.999
r2
values, consisting of 0.53 ng/ml as the lower limit of quantification (LLOQ). Analytes
were subjected to pretreatment by liquid-liquid extraction (LLE) procedure with average
extraction recovery findings within 99.93±5.04%. Method accuracy findings were
present in between 96.44% to 104.31%, and the assessed percentage relative standard
deviation findings for within and between run precision were ≤ 4.68%. Conclusion: The
developed LC-MS/MS procedure for quantitating nitazoxanide in the biological matrix
was suitable for routine analysis of patients’ blood samples for pharmacokinetic studies
and drug monitoring.
PHARMACEUTICS
Determination of nitazoxanide in biological matrices by LC-MS/MS technique: method development and validation - Vol.56(2), Apr-June - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 539-545p.
Background: Determination of pharmaceuticals in the biological matrices is essential for
toxicologic and pharmacokinetic applications. The main objective of the current work
was to develop a bioanalytical method for quantifying nitazoxanide in biological samples
by LC-MS/MS. Materials and Methods: Chromatographic elution of nitazoxanide and
linagliptin were achieved on C18
-hypersil (5 μ, 50x4.6mm) stationary phase with mobile
phase consisting of acetonitrile and 0.1% HCOOH (75:15, v/v) processed at 0.8 ml/min
flow rate. Linagliptin was utilized as an internal standard (IS). Results: The method
was linear in the concentration levels of 0.53–21.2 ng/ml with more than 0.999
r2
values, consisting of 0.53 ng/ml as the lower limit of quantification (LLOQ). Analytes
were subjected to pretreatment by liquid-liquid extraction (LLE) procedure with average
extraction recovery findings within 99.93±5.04%. Method accuracy findings were
present in between 96.44% to 104.31%, and the assessed percentage relative standard
deviation findings for within and between run precision were ≤ 4.68%. Conclusion: The
developed LC-MS/MS procedure for quantitating nitazoxanide in the biological matrix
was suitable for routine analysis of patients’ blood samples for pharmacokinetic studies
and drug monitoring.
PHARMACEUTICS